Company intelligence / Profile preview
AltrixBio
Cambridge, Massachusetts, United Statesaltrixbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
LuCI™ has shown in pre-clinical models to modulate nutrient contact with the bowel mucosa and lower glucose response, potentially replicating the effects of gastric bypass surgery for diabetes treatment[1][3]
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Small molecules (repurposed drug)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on AltrixBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AltrixBio.